ResultsIQ

ResultsIQ › Latest results › Jupiter Life Line Hospitals Limited

Jupiter Life Line Hospitals Limited Q2 FY27 earnings call summary

NSE: JLHL · BSE: 543980

Earnings call of 26 Oct 2026, summarised by AI from the filing.

No financial guidance given; maintenance capex guided at ₹10-20 cr per unit on average over 4-5 years.

Key takeaways

  1. Guidance No financial guidance given; maintenance capex guided at ₹10-20 cr per unit on average over 4-5 years.
  2. Dombivli EBITDA drag narrowed to ₹20 lakhs in Q2 FY27 from ₹9.5 cr in Q1 FY27, partly on seasonal infectious disease admissions.
  3. Risk Oncology drug margin cap from 1 November not modelled; impact on revenue and EBITDA unknown.

Original filing on BSE

Jupiter Life Line Hospitals Limited Q2 FY27 results

As filed: Revenue ₹457 cr (+16% year on year), EBITDA ₹107 cr (+16% year on year), PAT ₹56.4 cr (−1% year on year), EBITDA margin 23.4% (+6 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹411 cr (+18% year on year), EBITDA ₹79.3 cr (+2% year on year), PAT ₹37.5 cr (−15% year on year), EBITDA margin 19.3% (−313 bps). Score 30 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 313 bps year on year. Profit fell 23% from last quarter. Revenue rose ₹63.0 cr on a year ago, more than the ₹61.0 cr it added the year before. Share price after the results: −9.1% in 28 days (Nifty 500: +0.3%).
  • Q4 FY26: Revenue ₹388 cr (+19% year on year), EBITDA ₹89.2 cr (+13% year on year), PAT ₹48.8 cr (+8% year on year), EBITDA margin 23.0% (−117 bps). Score 51 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was well below it. EBITDA margin fell 117 bps year on year. Revenue rose ₹60.8 cr on a year ago, more than the ₹37.0 cr it added the year before. Share price after the results: −0.8% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹365 cr (+14% year on year), EBITDA ₹83.4 cr (+10% year on year), PAT ₹42.5 cr (−6% year on year), EBITDA margin 22.8% (−84 bps). Score 32 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were well below the company's own trend. EBITDA margin fell 84 bps year on year. Revenue fell 7% from last quarter. Revenue rose ₹44.4 cr on a year ago, against ₹48.0 cr the year before. Share price after the results: −3.5% in 28 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹394 cr (+22% year on year), EBITDA ₹92.0 cr (+23% year on year), PAT ₹57.0 cr (+10% year on year), EBITDA margin 23.4% (+13 bps). Score 56 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 13 bps year on year. Share price after the results: −7.7% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹348 cr (+21% year on year), EBITDA ₹78.0 cr (+22% year on year), PAT ₹44.0 cr (−2% year on year), EBITDA margin 22.4% (+11 bps). Score 54 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 11 bps year on year. Revenue rose ₹61.0 cr on a year ago, more than the ₹44.0 cr it added the year before. Share price after the results: −1.8% in 28 days (Nifty 500: −0.9%).
  • Q4 FY25: Revenue ₹327 cr (+13% year on year), EBITDA ₹79.0 cr (+27% year on year), PAT ₹45.0 cr (0% year on year), EBITDA margin 24.2% (+278 bps). Score 58 of 100, In line with trend. EBITDA margin rose 278 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 15% from last quarter. Share price after the results: +3.1% in 28 days (Nifty 500: +6.9%).
  • Q3 FY25: Revenue ₹321 cr (+18% year on year), EBITDA ₹76.0 cr (+23% year on year), PAT ₹53.0 cr (+20% year on year), EBITDA margin 23.7% (+97 bps). Score 65 of 100, In line with trend. EBITDA margin rose 97 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Jupiter Life Line Hospitals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.